Vaccine Young Adults
A phase II, multicentre, randomised, partially-blinded dose-ranging study to assess in healthy volunteers (18-57 years at enrolment), the immunogenicity and safety of an intradermal, trivalent, inactivated, split-virion influenza vaccine using a microinjection system in comparison with a licensed intramuscular control vaccine during 3 successive years, 9 visits per patient...
A Phase II, partially double-blind, randomised, controlled, primary vaccination single center study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulations of a meningococcal vaccine versus one subcutaneous dose of a marketed meningococcal vaccine in healthy adolescents / young adults aged 15-19 years. Subjects were stratified for enrolment according to age : one half of the subjects was aged 15-17 years, the other half of the subjects was aged 18-19 years...
A Phase II study to evaluate the safety, reactogenicity and immunogenicity of a vaccine in elderly patients. 4 visits foreseen with CMI samples and 6 months of safety follow up...
For this open-label multicenter uncontrolled trial, total of 210 adult and elderly subjects had to be included. Subjects had to be vaccinated as soon as the first commercial lots the vaccine were available, pending regulatory approval to conduct clinical trial. They had to be followed for a clinical safety assessment...
Hookipa Bivalent Vaccine 18-45 years old
HB-101: Bivalent vaccine containing two recombinant, replication-deficient lymphocytic chorio-meningitis virus (rLCMV) vectors, one expressing the gene of the pp65 protein of the human cytomegalovirus (HCMV) and one expressing the gene of the gB protein of HCMV.